DDInter1022 DDInter1658
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Lansoprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Lansoprazole {u} (Compound) binds {v} (Gene) ATP4A
Lansoprazole {u} (Compound) upregulates {v} (Gene) ZNF274
Lansoprazole {u} (Compound) is included by {v} (Pharmacologic Class) Inhibition Gastric Acid Secretion
Lansoprazole {u} (Compound) downregulates {v} (Gene) PRKACA
Lansoprazole {u} (Compound) causes {v} (Side Effect) Laboratory test abnormal
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Axitinib
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyanocobalamin
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capreomycin
Lansoprazole (Compound) resembles Rabeprazole (Compound)
Lansoprazole (Compound) binds ATP4A (Gene)
Lansoprazole (Compound) upregulates ZNF274 (Gene)
Lansoprazole (Compound) is included by Inhibition Gastric Acid Secretion (Pharmacologic Class)
Lansoprazole (Compound) downregulates PRKACA (Gene)
Lansoprazole (Compound) causes Laboratory test abnormal (Side Effect)
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Cyanocobalamin
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Capreomycin